Finding. Pancreatic alpha cells bank redox when glucose is around, using the pentose phosphate pathway, and they spend that cytosolic charge to keep PKA and glucagon alive when glucose falls. Intact-islet imaging shows PPP flux raising cytosolic redox potential. Antioxidants and a 5 mM glucose pre-incubation move PKA with that potential. Changing whole-body redox changes the mouse counterregulatory response. The mitochondrial textbook (low glucose, organelle, glucagon) is not the whole machine.
Why this paper matters
Everyone knows glucose inhibits glucagon. Fewer people know what glucose metabolism is doing inside the alpha cell that later has to secrete. This paper’s bet is a non-mitochondrial charging step. That is useful even if you came for mitochondria: it bounds how much of hypoglycemia counterregulation you can attribute to alpha-cell OXPHOS.
A redox battery that depends on recent 5 mM glucose is also a clinical-adjacent idea. An alpha cell that has not seen decent glucose may not be able to answer a crash.
What they actually measured
Live-cell redox potential in alpha cells in intact islets. PPP-linked elevation of cytosolic redox. Antioxidants and 5 mM pre-incubation versus PKA. Mouse whole-body redox versus counterregulation. Conclusion: prior glucose-driven redox charging is essential for glucagon at low glucose.
How to read the score
Around 70. Intact islets, a clear non-mitochondrial claim, a mouse counterregulatory clause. Confidence is medium. Score 71.
What to do with it
If you model glucagon, PPP, or islet redox, pull the alpha-cell imaging and the pre-incubation logic. Do not drop mitochondria from alpha-cell models; drop the idea that they are sufficient. The directional implication is that cytosolic redox history, set by pentose-phosphate glucose metabolism, licenses hypoglycemic glucagon.